Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: lucatumumab, selicrelumab, sotigalimab +7 | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 20 Parkinson's papers of 15,854 | 0.60 |
| pathways Reactome | 4 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7166
Sealed predictions
- CD40 in dopamine neurons, braak-0.14 (p 0.716) → +0.28 (p 0.472)receipt 7173
Swarm cases
receipt 7173: CD40 in dopamine neurons, braak
- power
- full sample +0.01 (p 0.976, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.908, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.00 (p 0.997, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.11, sign flips 7; without severely affected donors +0.01 (p 0.976, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD40 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts